Vascutek Restarts European Anaconda Trial; U.S. Study Planned For 2003
This article was originally published in The Gray Sheet
Executive Summary
Vascutek will seek FDA approval of an IDE in the first quarter of 2003 for the Anaconda abdominal aortic aneurysm repair system
You may also be interested in...
Terumo’s $170 Mil. Vascutek Purchase Builds Cardiovascular Offerings
Terumo Medical's annual sales will approach $230 mil. through the purchase of Centerpulse's Vascutek vascular graft division. A definitive purchase agreement was announced Oct. 4
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.